News

Bristol Myers Squibb announced that the U.S. FDA approved Opdivo®(nivolumab) 360 mg (injection for intravenous use) in combination with platinum-doublet chemotherapy every three weeks for three cycles for adult patients with resectable (tumors ≥4 cm or node positive) non-small...

Targovax ASA, a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, and Agenus, an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today...

Much of the reaction to President Joe Biden's State of the Union address concentrated on the president's repeated calls for Congress to allow Medicare to negotiate medication prices. That is why bringing prices under control was his top concern, Biden stated...

The UK government has put forth its intention to invest £260 million in cutting-edge medical research and development, as well as the manufacturing of innovative pharmaceuticals, gadgets, and diagnostics. Through digital clinical trial services and Trusted Research Environments, the Department of...

The head of the NHS revealed today that a breakthrough targeted medication treating lung cancer would be made accessible to anybody who qualifies, owing to a new drug deal. Sotorasib is a drug that targets a genetic abnormality known...

Croda International Plc, which uses smart science to improve lives, announces that it has entered a strategic collaboration with Statens Serum Institut (“SSI”), the leading Danish Governmental life-science research institute. Croda’s vaccine adjuvant specialists, based in Denmark, will exclusively manufacture,...

AbbVie announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its...